Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

124 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pharmacokinetic boosting of olaparib: A randomised, cross-over study (PROACTIVE-study).
Overbeek JK, Guchelaar NAD, Mohmaed Ali MI, Ottevanger PB, Bloemendal HJ, Koolen SLW, Mathijssen RHJ, Boere IA, Hamberg P, Huitema ADR, Sonke GS, Opdam FL, Ter Heine R, van Erp NP. Overbeek JK, et al. Among authors: van erp np. Eur J Cancer. 2023 Nov;194:113346. doi: 10.1016/j.ejca.2023.113346. Epub 2023 Sep 19. Eur J Cancer. 2023. PMID: 37806255 Free article. Clinical Trial.
Is rectal administration an alternative route for imatinib?
van Erp NP, Oostendorp RL, Guchelaar HJ, Schellens JH, Gelderblom H. van Erp NP, et al. Cancer Chemother Pharmacol. 2007 Sep;60(4):623-4. doi: 10.1007/s00280-006-0409-0. Epub 2007 Feb 8. Cancer Chemother Pharmacol. 2007. PMID: 17287936 Free article. No abstract available.
Sunitinib in refractory adrenocortical carcinoma: a phase II, single-arm, open-label trial.
Kroiss M, Quinkler M, Johanssen S, van Erp NP, Lankheet N, Pöllinger A, Laubner K, Strasburger CJ, Hahner S, Müller HH, Allolio B, Fassnacht M. Kroiss M, et al. Among authors: van erp np. J Clin Endocrinol Metab. 2012 Oct;97(10):3495-503. doi: 10.1210/jc.2012-1419. Epub 2012 Jul 26. J Clin Endocrinol Metab. 2012. PMID: 22837187 Clinical Trial.
Clinical pharmacokinetics of tyrosine kinase inhibitors.
van Erp NP, Gelderblom H, Guchelaar HJ. van Erp NP, et al. Cancer Treat Rev. 2009 Dec;35(8):692-706. doi: 10.1016/j.ctrv.2009.08.004. Epub 2009 Sep 5. Cancer Treat Rev. 2009. PMID: 19733976 Review.
Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity.
van Erp NP, Eechoute K, van der Veldt AA, Haanen JB, Reyners AK, Mathijssen RH, Boven E, van der Straaten T, Baak-Pablo RF, Wessels JA, Guchelaar HJ, Gelderblom H. van Erp NP, et al. Among authors: van der straaten t, van der veldt aa. J Clin Oncol. 2009 Sep 10;27(26):4406-12. doi: 10.1200/JCO.2008.21.7679. Epub 2009 Aug 10. J Clin Oncol. 2009. PMID: 19667267
Genetic polymorphisms associated with a prolonged progression-free survival in patients with metastatic renal cell cancer treated with sunitinib.
van der Veldt AA, Eechoute K, Gelderblom H, Gietema J, Guchelaar HJ, van Erp NP, van den Eertwegh AJ, Haanen JB, Mathijssen RH, Wessels JA. van der Veldt AA, et al. Among authors: van erp np, van den eertwegh aj. Clin Cancer Res. 2011 Feb 1;17(3):620-9. doi: 10.1158/1078-0432.CCR-10-1828. Epub 2010 Nov 19. Clin Cancer Res. 2011. PMID: 21097692
Correlation of toxicity and efficacy with pharmacokinetics (PK) of pegylated liposomal doxorubicin (PLD) (Caelyx®).
Boers-Sonderen MJ, van Herpen CM, van der Graaf WT, Desar IM, van der Logt MG, de Beer YM, Ottevanger PB, van Erp NP. Boers-Sonderen MJ, et al. Among authors: van der graaf wt, van erp np, van der logt mg, van herpen cm. Cancer Chemother Pharmacol. 2014 Sep;74(3):457-63. doi: 10.1007/s00280-014-2514-9. Epub 2014 Jun 26. Cancer Chemother Pharmacol. 2014. PMID: 24965180 Clinical Trial.
124 results